Special Purpose Vehicles in Pharma & Biotech – An In-Depth Explainer
Introduction
Special Purpose Vehicles (SPVs) play a pivotal role in the pharmaceutical and biotechnology sectors, facilitating innovative financing and structuring
Understanding Bankruptcy Remoteness in Biotech Royalty Financing Deals
Bankruptcy remoteness is a crucial concept in structuring financial deals — especially royalty financing transactions in the biotechnology and pharmaceutical industry.
The Weekly Term Sheet (41)
The week saw concentrated M&A activity focused on MASH and neurological assets totalling over $10 billion in deal
Milestones and Mirages: Biotech's Big-Deal Delusions
The Allure of the "Up To" Deal
Every so often, a biotech startup announces a blockbuster partnership with
Fund of the week: CureDuchenne Ventures
Executive Summary
CureDuchenne Ventures does not operate as a traditional venture capital firm. Instead, it represents a venture philanthropy model
Company of the week: Rome Therapeutics
Introduction
Rome Therapeutics is a Boston-based biotechnology company on a mission to drug the "dark genome" – the vast
Gene and Cell Therapy at a Crossroads – End of an Era or Strategic Pivot?
Introduction
In recent months, several major biopharma companies have dramatically scaled back or outright halted their gene and cell therapy
Pharma AI Data Pools: Promise and Pitfalls
Introduction
Bristol Myers Squibb (BMS) and Takeda have recently joined forces with several peers in an ambitious data-sharing venture to
Pharmaceutical Royalties as Securities: A Global Regulatory Assessment
Executive Overview
Pharmaceutical royalties occupy a complex regulatory landscape where classification depends fundamentally on structure rather than asset type. As
The Weekly Term Sheet (40)
Complete Biotech Deals Report: September 29-October 5, 2025
Executive Summary
The week of September 29-October 5, 2025, witnessed 19 distinct
